High expression of KIFC1 is a poor prognostic biomarker and correlates with TP53 mutation in lung cancer

Xiuying Li,Susu Wang,Pinglang Ruan,Ousman Bajinka,Weidong Zhang
DOI: https://doi.org/10.1097/md.0000000000037286
IF: 1.6
2024-03-09
Medicine
Abstract:Lung cancer is a common malignancy that affects human health, [ 1 ] and its incidence and death rate have increased rapidly in recent years in China and in the world at large. [ 2 ] From these incidence, non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases [ 3 , 4 ] while lung adenocarcinoma (LUAD) accounts for more than 40% of lung cancer incidence. [ 5 ] The reported 5-year survival rate for lung cancer, according to the surveillance, epidemiology, and end results program in 2011, was 15.6%, [ 6 ] and the KEYNOTE-042 Study reported 5-year overall survival rates of up to 22%. [ 7 ] At present, despite the substantial advancements in immunotherapy and surgical interventions, the prognosis of LUAD is poor. Hence, there is an urgent need to identify new prognostic factors and immune-related therapeutic targets to enhance the screening, diagnosis, and treatment of NSCLC.
medicine, general & internal
What problem does this paper attempt to address?